PCSK9 and acute coronary syndrome: PRS has been analyzed in the populations of the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) [79] and Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab (ODYSSEY OUTCOMES) [80] trials of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i).